STAT3 can become maximally activated through phosphorylation at serine 727 [16]. Janus kinase inhibitors (JAKi), which prevent activation of STAT3 are already used in the clinic for patients with myeloproliferative disorders [17]. This evidence concerns the gene STAT3 and myeloproliferative disorder.